Literature DB >> 7837142

Measurement and prediction of radiological progression in early rheumatoid arthritis.

M J Plant1, J Saklatvala, A A Borg, P W Jones, P T Dawes.   

Abstract

OBJECTIVE: To compare radiological scoring systems in early RA, and then to determine if the rate of radiological progression in the first year of disease (RRP01) predicts the subsequent rate of progression up to 8 years (RRP1-8).
METHODS: Hand and feet radiographs were performed at 0, 1, 2 and 8 years in 65 patients presenting with nonerosive RA and symptoms for less than 3 years. All films were scored by Sharp's method; Sharp, Larsen and carpometacarpal (CMC) ratio methods were compared in 23 patients.
RESULTS: Significant change in score was detected over the first year using Sharp (median of 15.5 vs 7.5, p < 0.00002) and Larsen (30.5 vs 22.5, p < 0.0002), but not CMC ratio (1.13 vs 1.14, p = 0.07). Sharp had greater range and sensitivity of change, and had better inter and intraobserver reproducibility. RRP01 showed a skewed distribution (median 0.7 units/month; range -0.3 to +6.1). Spearman correlation between RRP01 and RRP1-8 was r = 0.57, p < 0.001.
CONCLUSION: Both Sharp and Larsen indices are sensitive to change in the first year of RA, but Sharp has advantages of greater sensitivity and reproducibility: CMC ratio is not useful. Radiological progression rate in the first year correlates only moderately with subsequent rate of progression up to 8 years. This suggests that radiological progression is nonuniform and that different patterns of progression over time may exist.

Entities:  

Mesh:

Year:  1994        PMID: 7837142

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  16 in total

1.  The relation between joint erosion and generalized osteoporosis and disease activity in patients with rheumatoid arthritis.

Authors:  Filiz Sivas; Nurdan Barça; Mustafa Onder; Kürşat Ozoran
Journal:  Rheumatol Int       Date:  2006-04-20       Impact factor: 2.631

2.  Examining radiographic outcomes over time.

Authors:  Grace S Park; Weng Kee Wong; Dinesh Khanna; Richard H Gold; Harold E Paulus
Journal:  Rheumatol Int       Date:  2013-10-29       Impact factor: 2.631

Review 3.  Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages.

Authors:  S Boini; F Guillemin
Journal:  Ann Rheum Dis       Date:  2001-09       Impact factor: 19.103

4.  Radiographic estimation in seropositive and seronegative rheumatoid arthritis.

Authors:  Vjollca Sahatçiu-Meka; Sylejman Rexhepi; Suzana Manxhuka-Kërliu; Mjellma Rexhepi
Journal:  Bosn J Basic Med Sci       Date:  2011-08       Impact factor: 3.363

5.  Disease activity and the course of elbow joint deterioration over 10 years in the patients with early rheumatoid arthritis.

Authors:  Asami Abe; Hajime Ishikawa; Akira Murasawa; Kiyoshi Nakazono
Journal:  Clin Rheumatol       Date:  2007-12-20       Impact factor: 2.980

6.  Associations of HLA-DRB and -DQB genes with two and five year outcome in rheumatoid arthritis.

Authors:  K Eberhardt; E Fex; U Johnson; F A Wollheim
Journal:  Ann Rheum Dis       Date:  1996-01       Impact factor: 19.103

Review 7.  Pursuit of optimal outcomes in rheumatoid arthritis.

Authors:  David L Scott
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 8.  A critical appraisal of radiographic scoring systems for assessment of juvenile idiopathic arthritis.

Authors:  Andrea S Doria; Paul S Babyn; Brian Feldman
Journal:  Pediatr Radiol       Date:  2006-03-22

9.  Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis.

Authors:  Shahin Jamal; Kaushik Patra; Edward C Keystone
Journal:  Clin Rheumatol       Date:  2008-12-09       Impact factor: 2.980

Review 10.  Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?

Authors:  Sergio Schwartzman; Roy Fleischmann; G James Morgan
Journal:  Arthritis Res Ther       Date:  2004-06-21       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.